Saxo Morningstar Moat CHF Q4 2020 commentary

SaxoSelect Commentaries
Saxo Bank

Instruments traded
Stocks
Asset classesGlobal equities (excluding emerging markets)
Investment styleHigh quality stocks offering attractive dividends 
Dividend Yield
 1.5%
Quarterly return46.1% (net of fees)
Annualised volatility (since inception)26.2% 

Market overview

Who would have thought we’d be here, in early 2021, with peak global COVID-19 cases, a terribly weak economy, and near-record high markets. For humanity, we are gladly waving goodbye to 2020, but for markets we have endured a period of surprising benefit. Global stocks, corporate bonds, real estate, gold, commodities, and even bitcoin have all moved forward and delivered positive performance. 

In this regard, the final three months of 2020 was a strong one by historical standards—which did have some substantive developments. It is a clear case of market participants looking over the horizon, with the vaccine rollouts combining with a perception of greater political stability. The wave of “good news” comes with many fascinating and constructive sub plots. One of the most interesting happened in the fourth quarter of 2020, where small-cap value stocks bucked a multi-year trend to join the winner’s list. This was partly marked by President-elect Biden’s victory (the so-called blue wave) but is also a vision for life after lockdowns—with the reopening of the economy considered a positive for economically-sensitive and cyclical stocks. Company defaults and bankruptcies also remain low globally, defying the doomsayers, supported by record stimulus and the cheapest borrowing rates ever seen. This last point cannot be underplayed, with corporate bond spreads tightening to the lowest levels in history, perhaps reflecting expectations that a return to economic normality is still a long way off on the horizon.

Here are some of the fourth-quarter and full-year 2020 highlights:

  • Global stocks rose meaningfully in the fourth quarter, finishing 2020 with healthy overall returns given the circumstances. At year-end, the U.S. market had rallied as much as 70% from March lows.
  • Dividend stocks bounced back strongly in the fourth quarter but lagged the broader market for the year. Likewise, emerging-markets stocks outperformed developed markets during the fourth quarter. 
  • Despite a fourth-quarter rally, energy stocks were the worst-performing sector for the fourth consecutive year. At the other end, consumer cyclical and technology stocks soared.
  • Small-value stocks topped the Morningstar Style Box in the fourth quarter, but value stocks still trail growth stocks by massive margins for longer time frames.
  • Among fixed income, interest-rate-sensitive bonds were one of the rare assets to fall in the fourth quarter. Meanwhile, riskier high-yield and emerging-markets bond categories performed the best.
  • Inflation hedges, such as inflation-protected securities and gold, all had a strong 2020 while safe-haven currencies suffered.

Exhibit 1: The breadth of the strong equity performance has been noteworthy, with the fourth quarter rally pulling most global markets into positive territory.  

global_market_borometer

 

Portfolio performance (net of fees)

Oct1.00%
Nov
34.5%
Dec
7.59%
2020
21.3
Since inception (May 2017): 
45.6%

Top 10 portfolio holdings (as of 31/12/2020)

42.5% of total portfolio

NameWeight (%)
Nordstrom Inc5.32
Adient PLC4.91
Sabre Corp4.44
Baidu Inc ADR4.42
Lyft Inc Class A4.17
Banco Santander SA4.02
Tapestry Inc3.92
WESCO International Inc3.86
Core Laboratories NV3.84
Livent Corp3.63

Top Performers (Below performance figures are total return Q4 EUR):

  • Rolls Royce Holdings PLC. Share price went up 152.7% in Q4 and according to Morningstar proprietary analysis, the stock trades at a premium to fair value. The position has been sold in the latest rebalance as the team believes that the outlook for Rolls-Royce and the successful implementation of its long-term growth strategy appears to be highly uncertain.
  • Nordstrom Inc. Share price went up 150.9% in Q4 and according to Morningstar proprietary analysis, the stock trades at a discount to fair value. The investment management team believes that although Nordstrom has been greatly impacted by Corona virus, its brand power should hold.
  • Nordstrom is a fashion retailer that operates approximately 100 department stores in the U.S. and Canada and approximately 250 outlet stores under the names Nordstrom Rack and Last Chance. The company also operates e-commerce sites. Nordstrom’s largest merchandise categories are women’s apparel (31% of sales) and shoes (24% of sales). Nordstrom, which traces its history to a shoe store opened in Seattle in 1901, continues to be partially owned and managed by members of the Nordstrom family.
  • Livent Corp. Share price went up 101.3% in Q4 and according to Morningstar proprietary analysis, the stock trades at a discount to fair value.

    Livent is a pure-play lithium producer formed when FMC spun off its lithium business in October 2018. Livent should benefit from increased lithium demand via higher electric vehicle adoption, as lithium is a key component of EV batteries. The company's low-cost lithium carbonate production comes from brine resources in Argentina. Livent also operates downstream lithium hydroxide conversion plants in the United States and China and has a 25% stake in a fully integrated Canadian lithium project.
  • Adient PLC. Share price went up 92.3% in Q4 and according to Morningstar proprietary analysis, the stock trades at a discount to fair value.

    Adient is the leading seating supplier to the industry with about one third of the global market as well as a dominant share in China of about 45%. Operations in China are accounted for under the equity method so most revenue there is unconsolidated. Unconsolidated seating revenue from joint ventures totalled $9.5 billion in fiscal 2020. The company is headquartered in Ireland but has corporate offices in the Detroit area. Fiscal 2020 consolidated revenue, excluding joint venture sales, was $12.7 billion.
  • Tapestry Inc. Share price went up 90.6% in Q4 and according to Morningstar proprietary analysis, the stock trades at a discount to fair value.

    Coach, Kate Spade, and Stuart Weitzman are the fashion and accessory brands that comprise Tapestry. The firm’s products are sold through about 1,500 company-operated stores, wholesale channels, and e-commerce in North America (62% of fiscal 2020 sales), Europe, Asia (32% of fiscal 2020 sales), and elsewhere. Coach (71% of fiscal 2020 sales) is best known for affordable luxury leather products. Kate Spade (23% of fiscal 2020 sales) is known for colorful patterns and graphics. Women’s handbags and accessories produced 68% of Tapestry's sales in fiscal 2020. Stuart Weitzman, Tapestry's smallest brand, generates nearly all (98%) of its revenue from women’s footwear.

Worst Performers:

  • Biogen Inc. Share price went down 17.3% in Q4. The investment management team has lowered its fair value estimate following a Food and Drug Administration advisory committee meeting that was highly sceptical of Biogen's regulatory filing for Alzheimer's disease drug candidate aducanumab. and according to Morningstar proprietary analysis. Although the stock still trades at a discount to fair value.  

    Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. 
  • Bayer AG. Share price went down 9.67% in Q4 and according to Morningstar proprietary analysis, the stock trades at a discount to fair value.

    Bayer is a German healthcare and agriculture conglomerate. Healthcare provides just over half of the company's sales and includes pharmaceutical drugs as well as vitamins. The company has a crop science business that includes seeds, pesticides, herbicides, and fungicides, which was expanded through the acquisition of Monsanto.

  • VMware Inc. Share price went down 6.44% in Q4 and according to Morningstar proprietary analysis, the stock trades at a discount to fair value. 

    VMware, a majority-owned subsidiary of Dell, is an industry leader in virtual machines for data center servers and computer desktops. The software provider operates in the three segments of licenses, maintenance, and professional services. Customers include enterprises utilizing data centers, end-user computing, cloud providers, and software-defined networking. The Palo Alto, California, firm operates and sells on a global scale, with about half its revenue from the United States, through direct sales, distributors, and partnerships.

No other positions had negative performance in the quarter.

Outlook

With the big tail risks supposedly now behind us, many households continue to invest in earnest. In this regard, we seem to live in a two-pronged household dynamic, where a meaningful portion of white-collar households are saving more than ever (due to a lack of spending), while many others are finding it very tough.   

Looking to the future, investors must consider the risks they cannot see, or at least those they have not given weight to. For example, inflation and how we will ever unwind the record debt binge of 2020 could have untold consequences. Yet, above all else, investors need to weigh the valuations they are paying, as we have seen extreme divergences that presents both an opportunity and a risk. 

As Warren Buffett once said, “Only when the tide goes out do you discover who's been swimming naked”. We remain confident that our positions are in the best interests of our clients—acknowledging tomorrow’s challenges and working towards a prosperous 2021 with good financial decision making.   

Disclaimer

Any information found in this document, including performance information and statistics are subject to change. You can find the latest updated pricing information on the description page for each available portfolio. In providing this material Saxo Bank has not taken into account any particular recipient’s investment objectives, special investment goals, financial situation, and specific needs and demands and nothing herein is intended as a recommendation for any recipient to invest or divest in a particular manner and Saxo Bank assumes no liability for any recipient sustaining a loss from trading in accordance with a perceived recommendation. All investments entail a risk and may result in both profits and losses, and all capital is at risk. In particular investments in leveraged products, such as but not limited to foreign exchange, derivatives and commodities can be very speculative and profits and losses may fluctuate both violently and rapidly. Speculative trading is not suitable for all investors and all recipients should carefully consider their financial situation and consult financial advisors in order to understand the risks involved and ensure the suitability of their situation prior to making any investment, divestment or entering into any transaction. Any mentioning herein, if any, of any risk may not be, and should not be considered to be, neither a comprehensive disclosure of risks nor a comprehensive description of such risks. Any expression of opinion may not reflect the opinion of Saxo Bank and all expressions of opinion are subject to change without notice (neither prior nor subsequent).

Saxo Bank (Schweiz) AG
Beethovenstrasse 33
CH-8002
Zürich
Switzerland

Contact Saxo

Select region

Switzerland
Switzerland

All trading carries risk. Losses can exceed deposits on margin products. You should consider whether you understand how our products work and whether you can afford to take the high risk of losing your money. To help you understand the risks involved we have put together a series of Key Information Documents (KIDs) highlighting the risks and rewards related to each product. The KIDs can be accessed here or within the trading platform. Please note that the full prospectus can be obtained free of charge from Saxo Bank (Switzerland) ltd. or the issuer.

This website can be accessed worldwide however the information on the website is related to Saxo Bank (Switzerland) Ltd. All clients will directly engage with Saxo Bank (Switzerland) Ltd. and all client agreements will be entered into with Saxo Bank (Switzerland) Ltd. and thus governed by Swiss Law.

The content of this website represents marketing material and has not been notified or submitted to any supervisory authority.

If you contact Saxo Bank (Switzerland) Ltd. or visit this website, you acknowledge and agree that any data that you transmit to Saxo Bank (Switzerland) Ltd., either through this website, by telephone or by any other means of communication (e.g. e-mail), may be collected or recorded and transferred to other Saxo Bank Group companies or third parties in Switzerland or abroad and may be stored or otherwise processed by them or Saxo Bank (Switzerland) Ltd. You release Saxo Bank (Switzerland) Ltd. from its obligations under Swiss banking and securities dealer secrecies and, to the extent permitted by law, data protection laws as well as other laws and obligations to protect privacy. Saxo Bank (Switzerland) Ltd. has implemented appropriate technical and organizational measures to protect data from unauthorized processing and disclosure and applies appropriate safeguards to guarantee adequate protection of such data.

Apple, iPad and iPhone are trademarks of Apple Inc., registered in the U.S. and other countries. App Store is a service mark of Apple Inc.